
LIVANOVA PLC
LIVNNASDAQTrading Snapshot
- Day Range
- $78.23 โ $79.49
- 52-Week Range
- $48.57 โ $85.76
- Volume
- $2.81B
- Avg Volume
- $1.90B
- Shares Outstanding
- 54.9M
- Next Earnings
- Oct 2, 2026
Fundamentals Snapshot
- Annual Revenue
- $1.39B
- Last Q Revenue
- $391M
- P/E Ratio
- 22.2
- P/S Ratio
- 2.8x
- EPS (TTM)
- $3.38
- Dividend Yield
- โ
Why Investors Own LIVN
- โHigh-growth profile โ revenue up +17.7% YoY with expanding US Equity exposure.
- โHealthy economics โ 51% gross margin and 18% free-cash-flow margin.
- โNew products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About LIVANOVA PLC
LivaNova PLC is a global medical technology company dedicated to developing, manufacturing, and marketing a variety of therapeutic solutions. The company operates through three key segments. Its Cardiopulmonary division provides essential products for heart-lung procedures, such as oxygenators, heart-lung machines, and various perfusion systems. The Neuromodulation segment is known for its VNS Therapy System, an implantable device that delivers vagus nerve stimulation to treat drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. This segment is also advancing the VITARIA System, which employs VNS for heart failure, through clinical development. The Advanced Circulatory Support segment offers temporary life support solutions, including both cardiopulmonary and respiratory support technologies. LivaNova serves a wide range of medical professionals, including perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals and healthcare providers. The company's products are distributed globally through both its direct sales force and independent distributors. Additionally, LivaNova has a research collaboration with Verily aimed at discovering clinical biomarkers for depression. Founded in 1987, the company is headquartered in London, United Kingdom.
Otter Score Breakdown
โAnalyst Ratings
โLatest News & Updates

LivaNova Q2 Earnings & Revenues Beat Estimates, '26 Outlook Raised
LIVN's Q2 earnings and revenues beat estimates as Cardiopulmonary and Epilepsy growth fuels margin gains and a raised 2026 outlook.

LivaNova PLC Q2 2026 Earnings Call Summary
Moby summary of LivaNova PLC's Q2 2026 earnings call

LivaNova PLC (LIVN) (Q2 2026) Earnings Call Highlights: Record Revenue and EPS, Raised Guidance ...
LivaNova PLC (LIVN) delivers 9.8% constant currency revenue growth, raises full-year outlook, and secures key oxygenator supply agreement.

LivaNova Q2 Earnings Call Highlights
LivaNova (NASDAQ:LIVN) reported record quarterly revenue and adjusted earnings per share for the second quarter of 2026, citing double-digit reported growth across its Cardiopulmonary and Epilepsy businesses. The company raised its full-year revenue and adjusted EPS outlook while reducing its adjust

LivaNova PLC 2026 Q2 - Results - Earnings Call Presentation
2026-08-05. The following slide deck was published by LivaNova PLC in conjunction with their 2026 Q2 earnings call.
Needham Maintains Buy on LivaNova, Raises Price Target to $93
Needham analyst Mike Matson maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $81 to $93.